Back to search results

Study of NXP900 with Osimertinib for Advanced, EGFR-Mutated Lung Cancer

This study is testing a new combination treatment for advanced non-small cell lung cancer (NSCLC) that has a specific change in the EGFR gene. Researchers are combining NXP900, which is a drug that blocks certain proteins called SRC family kinases (SFK), with osimertinib, a standard treatment for EGFR-mutated lung cancer. You might be able to join if you are 18 or older, have advanced or metastatic EGFR-mutated NSCLC, and have already been treated with osimertinib. The study will look at how safe the combination is by tracking side effects and lab changes, and how well it works by measuring how many people respond to the treatment and for how long. The study plans to enroll 18 participants.

Study design
This is an open-label, multi-center Phase 1b study, meaning both you and your doctors will know which treatments you are receiving. It plans to enroll 18 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for treatment-related side effects and lab changes for up to 30 days after treatment. Your response to treatment will be measured for up to approximately 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07315113

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Nuvectis Pharma, Inc.
~18 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:NXP900Osimertinib

At a glance

Recruiting sites
5 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients with treatment related adverse events and/or clinical laboratory abnormalities
Measured over Up to 30 days post treatment
+3 more outcomes measured

Conditions

EGFR Mutation Positive Non-small Cell Lung Cancer
EGFR Mutated Non-small Cell Lung Cancer Patients

Explore related trials

Lung Non-Small Cell CarcinomaSoluble Epidermal Growth Factor Receptor

Where it's being run

6 sites across 6 states
Maryland1
Massachusetts1
Oregon1
Pennsylvania1
Texas1
Virginia1

Study leadership

  • Zofia Piotrowska, MD, MHS · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Erin Belshaw
[email protected]
12016278129
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of patients with treatment related adverse events and/or clinical laboratory abnormalitiesUp to 30 days post treatment
  • Objective response rate (ORR)Up to approximately 12 months

    Best response of complete response (CR) or partial response (PR) per RECIST 1.1

  • Duration of Response (DoR)Up to approximately 12 months

    Confirmed CR or PR from the first documented response to the date of documented disease progression or death.

  • Disease Control Rate (DCR)Up to approximately 12 months

    The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).